1887

Abstract

, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-valent pneumococcal conjugate vaccine (PCV7) was not introduced into the UK's routine childhood immunization programme until September 2006. After its introduction, a marked decrease in the incidence of pneumococcal disease was observed, both in the vaccinated and unvaccinated UK populations. However, pneumococci are highly diverse and serotype prevalence is dynamic. Conversely, PCV7 targets only a limited number of capsular types, which appears to confer a limited lifespan to the observed beneficial effects. Shifts in serotype distribution have been detected for both non-invasive and invasive disease reported since PCV7 introduction, both in the UK and elsewhere. The pneumococcal protein D conjugate vaccine (PHiD-CV, Synflorix; GlaxoSmithKline) and 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13; Pfizer) have been newly licensed. The potential coverage of the 10- and 13-valent conjugate vaccines has also altered alongside serotype shifts. Nonetheless, the mechanism of how PCV7 has influenced serotype shift is not clear-cut as the epidemiology of serotype prevalence is complex. Other factors also influence prevalence and incidence of pneumococcal carriage and disease, such as pneumococcal diversity, levels of antibiotic use and the presence of risk groups. Continued surveillance and identification of factors influencing serotype distribution are essential to allow rational vaccine design, implementation and continued effective control of pneumococcal disease.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.020016-0
2011-01-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/1/1.html?itemId=/content/journal/jmm/10.1099/jmm.0.020016-0&mimeType=html&fmt=ahah

References

  1. Bättig, P., Hathaway, L. J., Hofer, S. & Mühlemann, K. ( 2006; ). Serotype-specific invasiveness and colonization prevalence in Streptococcus pneumoniae correlate with the lag phase during in vitro growth. Microbes Infect 8, 2612–2617.[CrossRef]
    [Google Scholar]
  2. Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J. R., Elvin, L., Ensor, K. M., Hackell, J. & other authors ( 2000; ). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19, 187–195.[CrossRef]
    [Google Scholar]
  3. Black, S. B. M., Shinefield, H. R. M., Ling, S. M. M., Hansen, J., Fireman, B. M., Spring, D. M., Noyes, J. M., Lewis, E. M., Ray, P. M. & other authors ( 2002; ). Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21, 810–815.[CrossRef]
    [Google Scholar]
  4. Black, S., Shinefield, H., Baxter, R., Austrian, R., Bracken, L., Hansen, J., Lewis, E. & Fireman, B. ( 2004; ). Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23, 485–489.[CrossRef]
    [Google Scholar]
  5. Block, S. L., Hedrick, J., Harrison, C. J., Tyler, R., Smith, A., Findlay, R. & Keegan, E. ( 2004; ). Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 23, 829–833.[CrossRef]
    [Google Scholar]
  6. Brueggemann, A. B., Griffiths, D. T., Meats, E., Peto, T. E., Crook, D. W. & Spratt, B. G. ( 2003; ). Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187, 1424–1432.[CrossRef]
    [Google Scholar]
  7. Brueggemann, A. B., Peto, T. E., Crook, D. W., Butler, J. C., Kristinsson, K. G. & Spratt, B. G. ( 2004; ). Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 190, 1203–1211.[CrossRef]
    [Google Scholar]
  8. Burman, L. A., Norrby, R. & Trollfors, B. ( 1985; ). Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 7, 133–142.[CrossRef]
    [Google Scholar]
  9. Calix, J. J. & Nahm, M. H. ( 2010; ). A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J Infect Dis 202, 29–38.[CrossRef]
    [Google Scholar]
  10. Cao, J., Chen, D., Xu, W., Chen, T., Xu, S., Luo, J., Zhao, Q., Liu, B., Wang, D. & other authors ( 2007; ). Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 25, 4996–5005.[CrossRef]
    [Google Scholar]
  11. Cao, J., Li, D., Gong, Y., Yin, N., Chen, T., Wong, C. K., Xu, W., Luo, J., Zhang, X. & other authors ( 2009; ). Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 156, 52–60.[CrossRef]
    [Google Scholar]
  12. Carter, R. J. F. ( 2006; ). Infants too young to receive pneumococcal conjugate vaccine benefit from herd immunity. Thorax 61, 610.[CrossRef]
    [Google Scholar]
  13. Casey, J. R., Adlowitz, D. G. & Pichichero, M. E. ( 2010; ). New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 29, 304–309.
    [Google Scholar]
  14. CDC ( 2005; ). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54, 893–897.
    [Google Scholar]
  15. CDC ( 2009; ). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine – United States, 1997–2006. MMWR Morb Mortal Wkly Rep 58, 1–4.
    [Google Scholar]
  16. Clarke, S. C., Jefferies, J. M., Smith, A. J., McMenamin, J., Mitchell, T. J. & Edwards, G. F. S. ( 2006; ). Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland. J Clin Microbiol 44, 1224–1228.[CrossRef]
    [Google Scholar]
  17. Coffey, T. J., Enright, M. C., Daniels, M., Morona, J. K., Morona, R., Hryniewicz, W., Paton, J. C. & Spratt, B. G. ( 1998; ). Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 27, 73–83.[CrossRef]
    [Google Scholar]
  18. Committee on Infectious Diseases ( 2000; ). Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106, 362–366.[CrossRef]
    [Google Scholar]
  19. Dagan, R., Givonâ-Lavi, N., Leibovitz, E., Greenberg, D. & Porat, N. ( 2009; ). Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 199, 776–785.[CrossRef]
    [Google Scholar]
  20. Department of Health ( 2006; ). Important changes to the childhood immunisation programme, PL/CMO/2006/1.
  21. Department of Health ( 2010; ). Introduction of Prevenar 13® into the Childhood Immunisation Programme. Department of Health, Gateway reference: 13581.
  22. Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J., Herva, E., Takala, A., Kayhty, H., Karma, P. & other authors ( 2001; ). Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344, 403–409.[CrossRef]
    [Google Scholar]
  23. Grijalva, C. G., Nuorti, J. P., Arbogast, P. G., Martin, S. W., Edwards, K. M. & Griffin, M. R. ( 2007; ). Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369, 1179–1186.[CrossRef]
    [Google Scholar]
  24. Haber, M., Barskey, A., Baughman, W., Barker, L., Whitney, C. G., Shaw, K. M., Orenstein, W. & Stephens, D. S. ( 2007; ). Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25, 5390–5398.[CrossRef]
    [Google Scholar]
  25. Hamel, J., Charland, N., Pineau, I., Ouellet, C., Rioux, S., Martin, D. & Brodeur, B. R. ( 2004; ). Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72, 2659–2670.[CrossRef]
    [Google Scholar]
  26. Hanage, W. P., Kaijalainen, T. H., Syrjanen, R. K., Auranen, K., Leinonen, M., Makela, P. H. & Spratt, B. G. ( 2005; ). Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun 73, 431–435.[CrossRef]
    [Google Scholar]
  27. Hanage, W. P., Huang, S. S., Lipsitch, M., Bishop, C. J., Godoy, D., Pelton, S. I., Goldstein, R., Huot, H. & Finkelstein, J. A. ( 2007; ). Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 195, 347–352.[CrossRef]
    [Google Scholar]
  28. Hausdorff, W. P., Bryant, J., Paradiso, P. R. & Siber, G. R. ( 2000; ). Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30, 100–121.[CrossRef]
    [Google Scholar]
  29. Hausdorff, W. P., Dagan, R., Beckers, F. & Schuerman, L. ( 2009; ). Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27, 7257–7269.[CrossRef]
    [Google Scholar]
  30. Hicks, L. A., Harrison, L. H., Flannery, B., Hadler, J. L., Schaffner, W., Craig, A. S., Jackson, D., Thomas, A., Beall, B. & other authors ( 2007; ). Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 196, 1346–1354.[CrossRef]
    [Google Scholar]
  31. Hussain, M., Melegaro, A., Pebody, R. G., George, R., Edmunds, W. J., Talukdar, R., Martin, S. A., Efstratiou, A. & Miller, E. ( 2005; ). A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 133, 891–898.[CrossRef]
    [Google Scholar]
  32. Jefferies, J. M., Smith, A. J., Edwards, G. F. S., McMenamin, J., Mitchell, T. J. & Clarke, S. C. ( 2010; ). Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. J Clin Microbiol 48, 87–96.[CrossRef]
    [Google Scholar]
  33. Jin, P., Kong, F., Xiao, M., Oftadeh, S., Zhou, F., Liu, C., Russell, F. & Gilbert, G. L. ( 2009; ). First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J Infect Dis 200, 1375–1380.[CrossRef]
    [Google Scholar]
  34. Joint Committee on Vaccination and Immunisation ( 2009; ). Minutes of the Pneumococcal Subgroup on Tuesday 15th January. Department of Health.
    [Google Scholar]
  35. Kaye, P., Malkani, R., Martin, S., Slack, M., Trotter, C., Jit, M., George, R. & Miller, E. ( 2009; ). Invasive pneumococcal disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines. Presented at The 27th Annual Meeting of the European Society for Paediatric Infectious Diseases, 9–13 June 2009, Brussels.
  36. Kieninger, D. M., Kueper, K., Steul, K., Juergens, C., Ahlers, N., Baker, S., Giardina, P., Gruber, W. & Scott, D. ( 2008; ). Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healthy infants and toddlers. Presented at The 48th Annual ICAAC/IDSA 46th Annual Meeting, 25–28 October 2008, Washington DC.
  37. Kirkham, L.-A. S., Jefferies, J. M. C., Kerr, A. R., Jing, Y., Clarke, S. C., Smith, A. & Mitchell, T. J. ( 2006; ). Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J Clin Microbiol 44, 151–159.[CrossRef]
    [Google Scholar]
  38. Kyaw, M. H., Christie, P., Clarke, S. C., Mooney, J. D., Ahmed, S., Jones, I. G. & Campbell, H. ( 2003; ). Invasive pneumococcal disease in Scotland, 1999–2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 37, 1283–1291.[CrossRef]
    [Google Scholar]
  39. Lee, H., Nahm, M. H., Burton, R. & Kim, K. ( 2009; ). Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 16, 376–381.[CrossRef]
    [Google Scholar]
  40. Lucero, M. G., Dulalia, V. E., Nillos, L. T., Williams, G., Parreno, R. A., Nohynek, H., Riley, I. D. & Makela, H. ( 2009; ). Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev CD004977.
    [Google Scholar]
  41. Magee, A. D. & Yother, J. ( 2001; ). Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 69, 3755–3761.[CrossRef]
    [Google Scholar]
  42. McEllistrem, M. C., Adams, J., Mason, E. O. & Wald, E. R. ( 2003; ). Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 188, 1679–1684.[CrossRef]
    [Google Scholar]
  43. Melegaro, A. & Edmunds, W. J. ( 2004; ). Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22, 4203–4214.[CrossRef]
    [Google Scholar]
  44. Melegaro, A., Edmunds, W. J., Pebody, R., Miller, E. & George, R. ( 2006; ). The current burden of pneumococcal disease in England and Wales. J Infect 52, 37–48.[CrossRef]
    [Google Scholar]
  45. Morsczeck, C., Prokhorova, T., Sigh, J., Pfeiffer, M., Bille-Nielsen, M., Petersen, J., Boysen, A., Kofoed, T., Frimodt-Møller, N. & other authors ( 2008; ). Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clin Microbiol Infect 14, 74–81.[CrossRef]
    [Google Scholar]
  46. Mulholland, K. ( 2007; ). Perspectives on the burden of pneumonia in children. Vaccine 25, 2394–2397.[CrossRef]
    [Google Scholar]
  47. Nahm, M. H., Lin, J., Finkelstein, J. A. & Pelton, S. I. ( 2009; ). Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 199, 320–325.[CrossRef]
    [Google Scholar]
  48. Ogunniyi, A. D., Grabowicz, M., Briles, D. E., Cook, J. & Paton, J. C. ( 2007; ). Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75, 350–357.[CrossRef]
    [Google Scholar]
  49. Park, I. H., Park, S., Hollingshead, S. K. & Nahm, M. H. ( 2007a; ). Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 75, 4482–4489.[CrossRef]
    [Google Scholar]
  50. Park, I. H., Pritchard, D. G., Cartee, R., Brandao, A., Brandileone, M. C. C. & Nahm, M. H. ( 2007b; ). Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 45, 1225–1233.[CrossRef]
    [Google Scholar]
  51. Pichon, B., Beasley, L., Slack, M., Efstratiou, A., Miller, E. & George, R. ( 2008; ). Effect of the introduction of the pneumococcal conjugate vaccine in the UK childhood immunisation scheme on the genetic structure of paediatric invasive pneumococci. In The 6th International Symposium on Pneumococci and Pneumococcal Diseases, 8–12 June 2008, Reykjavik, Iceland.
  52. Pillai, D. R., Shahinas, D., Buzina, A., Pollock, R. A., Lau, R., Khairnar, K., Wong, A., Farrell, D. J., Green, K. & other authors ( 2009; ). Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 10, 642.[CrossRef]
    [Google Scholar]
  53. Pletz, M. W., Maus, U., Krug, N., Welte, T. & Lode, H. ( 2008; ). Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32, 199–206.[CrossRef]
    [Google Scholar]
  54. Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J. & other authors ( 2006; ). Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367, 740–748.[CrossRef]
    [Google Scholar]
  55. Rennels, M. B., Edwards, K. M., Keyserling, H. L., Reisinger, K. S., Hogerman, D. A., Madore, D. V., Chang, I., Paradiso, P. R., Malinoski, F. J. & other authors ( 1998; ). Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101, 604–611.[CrossRef]
    [Google Scholar]
  56. Richter, S. S., Heilmann, K. P., Dohrn, C. L., Riahi, F., Beekmann, S. E. & Doern, G. V. ( 2009; ). Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin Infect Dis 48, e23–e33.[CrossRef]
    [Google Scholar]
  57. Rodgers, G. L., Arguedas, A., Cohen, R. & Dagan, R. ( 2009; ). Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27, 3802–3810.[CrossRef]
    [Google Scholar]
  58. Sá-Leão, R., Nunes, S., Brito-Avô, A., Frazão, N., Simões, A. S., Crisóstomo, M. I., Paulo, A. C. S., Saldanha, J., Santos-Sanches, I. & other authors ( 2009; ). Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect 15, 1002–1007.[CrossRef]
    [Google Scholar]
  59. Scott, D. A., Komjathy, S. F., Hu, B. T., Baker, S., Supan, L. A., Monahan, C. A., Gruber, W., Siber, G. R. & Lockhart, S. P. ( 2007; ). Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25, 6164–6166.[CrossRef]
    [Google Scholar]
  60. Shakir, E., Cameron, C., Denham, B. & McMenamin, J. ( 2009; ). Respiratory and immunisation quarterly report. HPS Wkly Rep 43, 407–408.
    [Google Scholar]
  61. Silva, N. A., McCluskey, J., Jefferies, J. M. C., Hinds, J., Smith, A., Clarke, S. C., Mitchell, T. J. & Paterson, G. K. ( 2006; ). Genomic diversity between strains of the same serotype and multilocus sequence type among pneumococcal clinical isolates. Infect Immun 74, 3513–3518.[CrossRef]
    [Google Scholar]
  62. Sjöström, K., Spindler, C., Ortqvist, A., Kalin, M., Sandgren, A., Kühlmann-Berenzon, S. & Henriques-Normark, B. ( 2006; ). Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42, 451–459.[CrossRef]
    [Google Scholar]
  63. Smith, T., Lehmann, D., Montgomery, J., Gratten, M., Riley, I. D. & Alpers, M. P. ( 1993; ). Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol Infect 111, 27–39.[CrossRef]
    [Google Scholar]
  64. Spratt, B. G. & Greenwood, B. M. ( 2000; ). Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356, 1210–1211.[CrossRef]
    [Google Scholar]
  65. Stein, K. E. ( 1992; ). Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 165, S49–S52.[CrossRef]
    [Google Scholar]
  66. Tocheva, A. S., Jefferies, J. M. C., Christodoulides, M., Faust, S. N. & Clarke, S. C. ( 2010; ). Increase in serotype 6C pneumococcal carriage, United Kingdom. Emerg Infect Dis 16, 154–155.[CrossRef]
    [Google Scholar]
  67. Tyrrell, G. J., Lovgren, M., Chui, N., Minion, J., Garg, S., Kellner, J. D. & Marrie, T. J. ( 2009; ). Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000–2006. Vaccine 27, 3553–3560.[CrossRef]
    [Google Scholar]
  68. Väkeväinen, M., Eklund, C., Eskola, J. & Käyhty, H. ( 2001; ). Cross-reactivity of antibodies to Type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis 184, 789–793.[CrossRef]
    [Google Scholar]
  69. Weinberger, D. M., Trzcinski, K., Lu, Y., Bogaert, D., Brandes, A., Galagan, J., Anderson, P. W., Malley, R. & Lipsitch, M. ( 2009; ). Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 5, e1000476.[CrossRef]
    [Google Scholar]
  70. Wysocki, J., Tejedor, J. C., Grunert, D., Konior, R., Garcia-Sicilia, J., Knuf, M., Bernard, L., Dieussaert, I. & Schuerman, L. ( 2009; ). Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 28, S77–S88.[CrossRef]
    [Google Scholar]
  71. Zhang, Q., Choo, S. & Finn, A. ( 2002; ). Immune responses to novel pneumococcal proteins Pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun 70, 5363–5369.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.020016-0
Loading
/content/journal/jmm/10.1099/jmm.0.020016-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error